Cyclopharm posts record $17.5M FY26 revenue
- The medical imaging firm achieved a fifth consecutive record half-year sales result driven by American commercial expansion.
- US sales jumped 74% year-on-year, with active installations and customer site adoption driving the primary growth engine for the group's signature lung imaging product.
- Management is focused on expanding its footprint across the broad healthcare market to secure long-term recurring revenues.
Cyclopharm (ASX:CYC) delivered a record $17.5 million in revenue for the six months ended June 30, representing a 14% increase on the prior corresponding period.
The net loss after income tax for H1 was $8.8 million, compared with $7.7 million a year earlier.
“US Technegas revenue grew 74% year-on-year, with revenue-generating primary sites doubling from 35 on June 30, 2025, to 70 on June 30, each adding a recurring, accretive consumable revenue stream,” said Cyclopharm in its market announcement.
The business completed a $13.5 million institutional placement and share purchase plan while expanding its engaged pipeline to 1,684 locations as of Aug. 12.
The company stated that each new unit installation adds recurring consumable sales at gross margins approaching 95%.
Following the announcement, the Cyclopharm share price was up at $0.52.
The enterprise operates across 66 international markets supplying functional lung ventilation imaging tech, with third-party distribution sales generating $8.1 million during the period.
